SignalCorporate
Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?
AbbVie earnings beat prompts reassessment of ABBV investment case.
Context
What happened: AbbVie reported third quarter 2026 sales of US$17.4b and net income of US$4.2b, raised full year revenue and adjusted EPS guidance, and approved a 5.2% quarterly dividend increase to US$1.82 per share.
Key numbers: Q3 2026 sales US$17.4b; net income US$4.2b; dividend up 5.2% to US$1.82 per share, payable
Why it matters: The raised guidance and higher dividend rest on immunology and neuroscience products offsetting Humira and Imbruvica pressure. Consensus models assume earnings grow roughly 3.8x by 2029, leaving less room for disappointment if pricing or competition worsen.
Market: +1.4% today ($294.89), +30.7% YTD, 1.5x vol — as of 23:45 UTC
Verified: Q3_2026 (Oct 30) EPS $3.82 vs $3.77 est, +1.3% beat; next print ~Jan 29
Coverage: 3 outlets in 24h
What changed
AbbVie reported third quarter 2026 sales of US$17.4b and net income of US$4.2b, raised full year revenue and adjusted EPS guidance, and approved a 5.2% quarterly dividend increase to US$1.82 per share.
Why it matters
The raised guidance and higher dividend rest on immunology and neuroscience products offsetting Humira and Imbruvica pressure. Consensus models assume earnings grow roughly 3.8x by 2029, leaving less room for disappointment if pricing or competition worsen.
Market: +1.4% today ($294.89), +30.7% YTD, 1.5x vol — as of 23:45 UTC
Verified: Q3_2026 (Oct 30) EPS $3.82 vs $3.77 est, +1.3% beat; next print ~Jan 29